Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3

Objective: In the ARIEL3 study (NCT01968213), rucaparib maintenance treatment significantly improved progression-free survival (PFS) versus placebo in all predefined, nested cohorts (BRCA mutant; BRCA mutant + wildtype BRCA/high loss of heterozygosity; and intent-to-treat population). Here we analyzed postprogression outcomes to evaluate the durability of the clinical benefit of rucaparib maintenance treatment following disease progression in the subgroup of patients with tumors associated with a mutation in a prespecified, non-BRCA, homologous recombination repair (HRR) gene.